Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker

作者：Kiran Kumar Solingapuram Sai, Anirudh Sattiraju, Frankis G. Almaguel, Ang Xuan, Stephanie Rideout, Rahul S. Krishnaswamy, Joann Zhang, Denise Herpai, Waldemar Debinski, Akiva Mintz · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.16549 · 被引用次数：37 · 研究领域：Cancer Research and Treatments、Cancer Immunotherapy and Biomarkers、Cell Adhesion Molecules Research

// Kiran Kumar Solingapuram Sai 1, * , Anirudh Sattiraju 1, * , Frankis G. Almaguel 1 , Ang Xuan 1 , Stephanie Rideout 1 , Rahul S. Krishnaswamy 1 , JoAnn Zhang 2 , Denise M. Herpai 3 , Waldemar Debinski 3 and Akiva Mintz 1 1 Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA 2 MicroPET/CT Imaging Section, TriFoil Imaging, Chatsworth, CA, USA 3 Department of Cancer Biology, Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston Salem, NC, USA * These authors have contributed equally to this work Correspondence to: Kiran Kumar Solingapuram Sai, email: ksolinga@wakehealth.edu Akiva Mintz, email: amintz@wakehealth.edu Keywords: positron emission tomography (PET), high-grade glioma, doxycycline, biodistribution, IL13RA2 Received: January 25, 2017     Accepted: February 27, 2017     Published: March 24, 2017 ABSTRACT Peptides that target cancer cell surface receptors are promising platforms to deliver diagnostic and therapeutic payloads specifically to cancer but not normal tissue. IL13RA2 is a tumor-restricted receptor found to be present in several aggressive malignancies, including in the vast majority of high-grade gliomas and malignant melanoma. This receptor has been successfully targeted for diagnostic and therapeutic purposes using modified IL-13 ligand and more recently using a specific peptide, Pep-1L. In the current work, we establish the in vitro and in vivo tumor binding properties...